OXB - Ticker AI Digest

Oxford BioMedica PLC
631.00 | Today 0.96%
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (OXB) 0
No same-day market news for OXB on 2026-04-15.
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 1
OXB 06:01
Oxford BioMedica PLC
Licensing agreement with VVMF
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Oxford Biomedica (OXB) has entered into a licensing and option agreement with Viral Vector Manufacturing Facility (VVMF), an Australian CDMO, granting VVMF access to OXBs proprietary AAV and LV viral vector platforms. This five-year agreement, with a low single-digit million license fee and potential future payments, supports VVMFs development of viral vector manufacturing capabilities, particularly in the APAC region. The collaboration extends OXBs global reach, reinforces its position as a trusted viral vector CDMO, and positions Australia as a regional hub for high-quality cell and gene therapy manufacturing.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 1
OXB 06:01
Oxford BioMedica PLC
Launch of viral vector fast-track offering
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Oxford Biomedica (OXB) launches a fast-track offering for AAV and lentiviral vector development and manufacturing, reducing timelines by up to 50%. This service, designed for biotechs with time constraints, accelerates GMP manufacturing from 15 months to as little as 7 months for AAV vectors and 12-18 months to 9 months for lentiviral vectors. Utilizing proprietary platforms (inAAVateâ„¢ and LentiVectorâ„¢), OXB aims to help clients achieve clinical milestones faster, ultimately speeding patient access to transformative treatments.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 1
OXB 06:01
Oxford BioMedica PLC
Preliminary results for the year ended 31 Dec 2025
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Oxford Biomedica PLC (OXB) reported strong preliminary results for the year ended 31 December 2025, highlighting strategic execution, robust revenue growth, and positive Operating EBITDA. Key financial highlights include
**Revenue Growth** 33% increase to £170.9 million (constant currency), driven by growth in lentiviral vector GMP manufacturing, increased client progression, and expansion in procurement and storage services.
**Operating EBITDA** Achieved a profit of £8.1 million (constant currency), up from a £15.3 million loss in 2024, reflecting revenue growth and cost management.
**Revenue Backlog** Increased by 36% to £204 million, indicating strong future revenue potential.
**Strategic Expansion** Acquired an FDA-approved commercial-scale viral vector manufacturing facility in Durham, NC, enhancing global CDMO capabilities.
**New Commercial Agreement** Signed a multi-year agreement with Bristol Myers Squibb (BMS) for lentiviral vector manufacturing post-period.
**Financial Guidance** Projected 2026 revenues of £220-240 million with a 10% Operating EBITDA margin, and medium-term revenue growth of 25-30% with margins rising to at least 20% by 2027.
Operationally, OXB expanded its global CDMO network, improved efficiency, and strengthened its balance sheet through equity raises and loan facilities. The company also advanced its innovation efforts, particularly in AAV and lentiviral vector technologies, and enhanced its ESG commitments. The acquisition of the Durham facility and strategic partnerships underscore OXBs position as a global leader in cell and gene therapy CDMO services, poised for sustained growth and profitability.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 6
OXB 06:01
Oxford BioMedica PLC
Launch of viral vector fast-track offering
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Oxford Biomedica (OXB) launches a fast-track offering for AAV and lentiviral vector development and manufacturing, reducing timelines by up to 50%. This service, designed for biotechs with time constraints, accelerates GMP manufacturing from 15 months to as little as 7 months for AAV vectors and 12-18 months to 9 months for lentiviral vectors. Utilizing proprietary platforms (inAAVateâ„¢ and LentiVectorâ„¢), OXB aims to help clients achieve clinical milestones faster, ultimately speeding patient access to transformative treatments.
OXB 16:19
Oxford BioMedica PLC
Grant of Awards
OXB 06:01
Oxford BioMedica PLC
Total Voting Rights
OXB 14:31
Oxford BioMedica PLC
2026 Annual General Meeting notification
OXB 06:01
Oxford BioMedica PLC
Preliminary results for the year ended 31 Dec 2025
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Oxford Biomedica PLC (OXB) reported strong preliminary results for the year ended 31 December 2025, highlighting strategic execution, robust revenue growth, and positive Operating EBITDA. Key financial highlights include
**Revenue Growth** 33% increase to £170.9 million (constant currency), driven by growth in lentiviral vector GMP manufacturing, increased client progression, and expansion in procurement and storage services.
**Operating EBITDA** Achieved a profit of £8.1 million (constant currency), up from a £15.3 million loss in 2024, reflecting revenue growth and cost management.
**Revenue Backlog** Increased by 36% to £204 million, indicating strong future revenue potential.
**Strategic Expansion** Acquired an FDA-approved commercial-scale viral vector manufacturing facility in Durham, NC, enhancing global CDMO capabilities.
**New Commercial Agreement** Signed a multi-year agreement with Bristol Myers Squibb (BMS) for lentiviral vector manufacturing post-period.
**Financial Guidance** Projected 2026 revenues of £220-240 million with a 10% Operating EBITDA margin, and medium-term revenue growth of 25-30% with margins rising to at least 20% by 2027.
Operationally, OXB expanded its global CDMO network, improved efficiency, and strengthened its balance sheet through equity raises and loan facilities. The company also advanced its innovation efforts, particularly in AAV and lentiviral vector technologies, and enhanced its ESG commitments. The acquisition of the Durham facility and strategic partnerships underscore OXBs position as a global leader in cell and gene therapy CDMO services, poised for sustained growth and profitability.
OXB 06:01
Oxford BioMedica PLC
Licensing agreement with VVMF
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Oxford Biomedica (OXB) has entered into a licensing and option agreement with Viral Vector Manufacturing Facility (VVMF), an Australian CDMO, granting VVMF access to OXBs proprietary AAV and LV viral vector platforms. This five-year agreement, with a low single-digit million license fee and potential future payments, supports VVMFs development of viral vector manufacturing capabilities, particularly in the APAC region. The collaboration extends OXBs global reach, reinforces its position as a trusted viral vector CDMO, and positions Australia as a regional hub for high-quality cell and gene therapy manufacturing.

AI Crunch

Single-Ticker AI Crunch
OXB signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for Oxford BioMedica PLC. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full OXB AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for OXB on 2026-04-15.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
755622208
Enterprise Value
327833340
Public Float
50.28
Broker Target
842.857
Shares Out
120899550
Long Interest
94
Short Interest
6
Exchange
LSE
Currency Code
GBX
ISIN
GB00BDFBVT43
Market
LSE - MAIN MARKET
Sector
Pharmaceuticals and Biotechnology
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2026-04-09
Net Debt
9756000.0
Cash
96884000.0
EPS
-0.27
Net Income
-30128000.0
Revenue
168741000.0
Enterprise Value
327833340
Trailing PE
-
Forward PE
208.3333
Price Sales TTM
4.478
Price Book MRQ
7.5706
EV Revenue
4.402
EV EBITDA
307.9558

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
34.1457
Institutions As Of
2025-11-03
Avg Broker Target
698.125
Upside Vs Price
10.64%
Purchase Director Dealing
4
Sale Director Dealing
3
Purchase TR1
10
Sale TR1
2
Broker Coverage Rows
8
Institution Holders Tracked
5
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

AI Charts is armed for the next catalyst in OXB.

No same-day headline has printed on 2026-04-15 yet, but the latest digestion is ready below the chart workflow and the catalyst beacons can still map the recent tape.
Standby Tape Data 2026-04-15 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
0 Today
Catalyst Pulse
Waiting for a fresh same-day headline while recent digestion stays on deck.
16:19 Latest Tape Grant of Awards 06:01 Latest Tape Total Voting Rights
AI Charts Studio
OXB Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2026-04-15 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast 10.55%
RSI Gauge
Price Change
AI Forecast